Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02421718

Enrollment

10000

Registered

2015-04-21

Start date

2013-03-01

Completion date

2031-12-01

Last updated

2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Acute toxicity, Late toxicity, Prediction models

Brief summary

Motive: In order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from lung cancer patients. Goal: To set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life. A standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.

Interventions

RADIATIONRadiotherapy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with NSCLC or SCLC-LD or thymoma or lung metastases (treated with stereotactic radiotherapy) * Patients receiving radiotherapy dose \> 40 Gy

Exclusion criteria

* Failure to comply with any of the inclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Acute toxicity	Highest during and within 2 weeks after last day of radiation therapy	esophagitis (Common Terminology Criteria for Adverse Events, version 4.0)
Late toxicity	Highest within one year after last day of radiation therapy	esophagitis (Common Terminology Criteria for Adverse Events, version 4.0); pneumonitis (Common Terminology Criteria for Adverse Events, version 4.0)

Secondary

Measure	Time frame
Overall survival	at 1 year after first day of radiation therapy
Loco-regional tumor control	at 1 year after first day of radiation therapy

Countries

Netherlands

Contacts

CONTACTRobin Wijsman, MD PhD

r.wijsman@umcg.nl+31503615532

PRINCIPAL_INVESTIGATORRobin Wijsman, MD

University Medical Center Groningen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026